74226-22-5

74226-22-5 structure

Name	4-(2-imidazol-1-ylethoxy)benzoic acid,hydrochloride
Synonyms	Dazoxiben hydrochloride Dazoxiben HCl

Description	Dazoxiben is a potent and orally active thromboxane (TX) synthase inhibitor[1].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Prostaglandin Receptor Research Areas >> Inflammation/Immunology
Target	Thromboxane (TX) synthase[1]
In Vitro	Dazoxiben inhibits TXB2 production in clotting human whole blood with an IC50 of 0.3 μM and causes parallel enhancement of PGE2 greater than PGF2 alpha greater than 6-keto-PGF1 alpha production[1]. Dazoxiben inhibits TXB2 production in rat kidney glomeruli with an IC50 of 1.60 μM) than in rat whole blood (IC50= 0.32μM), and is not associated with changes in PGE2, PGF2 alpha and 6-keto-PGF1 alpha production[1].
In Vivo	Dazoxiben (intraperitoneal administration; 100 μg/kg) produces a marked prolongation of the tail bleeding time with 96.8 ± 10.8 secs[2].
References	[1]. Patrignani P, et al. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism.J Pharmacol Exp Ther. 1984 Feb;228(2):472-7. [2]. Yu SM, et al. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.Br J Pharmacol. 1994 Mar;111(3):906-12.

Hazard Codes	Xi

85938-29-0

~79%

74226-22-5

Literature: Ono Pharmaceutical Co., Ltd. Patent: US4461905 A1, 1984 ;

75912-57-1

~84%

74226-22-5

36616-30-5

74226-22-5

75912-98-0

74226-22-5

Literature: Biagi; Dell'Omodarme; Ferretti; Giorgi; Livi; Scartoni Farmaco, 1990 , vol. 45, # 11 p. 1181 - 1192